M&A Deal Summary |
|
---|---|
Date | 2021-05-28 |
Target | Lodo Therapeutics |
Sector | Life Science |
Buyer(s) | Zymergen |
Deal Type | Add-on Acquisition |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Founded | 2013 |
Sector | Information Technology |
Revenue | 17M USD (2021) |
Zymergen is a science and material innovation company rethinking biology and reimagining the world. The company partners with nature to create never-before-imagined materials and products across industries from agriculture to electronics, consumer care to pharmaceuticals, and more. It creates sustainable materials that are in use today, delivering value for Fortune 1000 companies with over $1 billion worth of products using Zymergen microbial innovations sold to date. Zymergen was formed in 2013 and is based in Emeryville, California.
DEAL STATS | # |
---|---|
Overall | 3 of 3 |
Sector (Life Science) | 3 of 3 |
Type (Add-on Acquisition) | 2 of 2 |
State (New York) | 1 of 1 |
Country (United States) | 3 of 3 |
Year (2021) | 1 of 1 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2020-03-19 |
enEvolv
Medford, Massachusetts, United States enEvolv, Inc. is a synthetic biology company that develops an enzyme and strain development platform to harness the power of evolution and create unique, commercial products by engineering the genomes of microbes. enEvolv was established in 2011 and is based in Medford, Massachusetts. |
Buy | - |